Hemogenyx Pharmaceuticals PLC Announces Clinical Trial Update and Grant of Share Awards

Core Insights - The independent Data Safety Monitoring Board (DSMB) has recommended the continuation of the Phase I clinical trial of HG-CT-1, a proprietary CAR-T therapy for relapsed or refractory acute myeloid leukemia (R/R AML) in adults, allowing for escalation to the next dose level [1] - Initial safety assessments for the first three patients treated at the lowest dose level showed no dose-limiting toxicities, indicating a positive safety profile for the therapy [1] Company Developments - Hemogenyx Pharmaceuticals plc has received clearance from the DSMB to proceed with the next dose level in its ongoing clinical trial [1] - The company is now opening recruitment for pediatric patients as part of the trial expansion [1] - The DSMB's recommendation is based on the successful safety data from the initial cohort of patients [1]